secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001654954-24-005886
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica Q1 revenue up 14% to $6.3M, net loss widens to $9.2M; FY guidance reaffirmed
--------------------------------------------------------------------------------

- Q1 2024 revenue $6.3M (+14% YoY) driven by 86% growth in Diagnostics and 9% in Therapeutic Devices.
- Net loss $9.2M ($0.01/share) vs $6.4M loss in Q1 2023; adjusted non-GAAP EBITDA loss $6.2M.
- Gross margin 66%; consumable revenue $4.0M (64% of sales), capital revenue $2.2M (+30% YoY).
- Cash and securities $90.9M at March 31, 2024, down from $100.5M at Dec 31, 2023.
- FY 2024 revenue guidance maintained at $31-35M, up ~39% at high end from $25.2M in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495424005886/0001654954-24-005886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495424005886/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-005886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer